Overview

Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine

Status:
RECRUITING

Trial end date:
2025-06-11

Target enrollment:

Participant gender:

Summary

Phase IIIb , longitudinal, multicenter, randomized, double-blind, to evaluate efficacy and safety of the fixed-dose combination of Desloratadine 5 mg / Betamethasone 0.25 mg versus Desloratadine 5 mg monotherapy as treatment for symptoms associated with allergic rhinitis.

Phase:

PHASE3

Details

Lead Sponsor:

Laboratorios Silanes S.A. de C.V.

Treatments:

Betamethasone
desloratadine